Table 3 Clinical trials providing information on tumour characteristics of patients with HCC who received TIPS
From: Risks and benefits of TIPS in HCC and other liver malignancies: a literature review
Author | Enrolled patients with HCC + TIPS | Tumour size (cm) | Location | Single (1–2 lesions) | Multiple (> 3 lesions) |
|---|---|---|---|---|---|
Larrey E, et al. 2022 [6] | 8 | 1.2–4.9 | Central: 1 Non-central: 7 | 8 | 0 |
Yan H, et al. 2022 [18] | 123 | NA | NA | 42 | 81 |
Qiu Z, et al. 2022 [15] | 42 | NA | NA | 9 | 33 |
Dong H, et al. 2021 [12] | 13 | NA | Central: 7 Non-central: 6 | NA | NA |
Tsauo J, et al. 2021 [17] | 126 | Max. 4.2 | NA | 98 | 28 |
Bettinger D, et al. 2015 [14] | 40 | 1.6-8 | Central: 15 Non-central: 25 | 21 | 19 |
Liu L, et al. 2014 [13] | 58 | 2.6–16 | NA | 38 | 20 |
Yao J, et al. 2015 [42] | 279 | Max. > 5 | NA | 270 | 9 |
Qiu B, et al. 2015 [78] | 209 | Max. > 5 | NA | 148 | 61 |